FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA, CBP Seize Counterfeit Weight Loss Drugs

Media reports indicate that FDA and Customs and Border Protection intercepted $270,000 worth of counterfeit and unapproved weight loss drugs in Cincin...

latest-news-card-1
Medical Devices

Piur Device Converting 2D Scans to 3D Cleared

FDA clears a Piur Imaging 510(k) for the Piur tUS Infinity that transforms existing 2D ultrasound devices into advanced 3D imaging systems for thyroid...

latest-news-card-1
Human Drugs

Lilly Sues FDA Over Retatrutide Designation

Lilly asks an Indiana federal court to overturn an FDA determination that the companys retatrutide is a drug rather than a biologic.

latest-news-card-1
Federal Register

Workshop on Live Biotherapeutics for Enterocolitis

Federal Register notice: FDA, CDC, and NIH announce an 11/25 public workshop entitled Live Biotherapeutic Products to Prevent Necrotizing Enterocoliti...

latest-news-card-1
Human Drugs

More Support for Treating All Biologics the Same

Two drug trade associations support an FDA approach to postapproval manufacturing changes in biosimilar and interchangeable biosimilar products.

latest-news-card-1
Human Drugs

FDA OKs AZs Tagrisso Lung Cancer Drug

FDA approves AstraZenecas Tagrisso for some non-small cell lung cancers.

latest-news-card-1
Human Drugs

Azurity Selling Unapproved Drugs: FDA

FDA warns Wilmington, MA-based Azurity Pharmaceuticals it is manufacturing and marketing unapproved new drugs with CGMP violations.

latest-news-card-1
Federal Register

Regulatory Review Period for Quviviq

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Idorsia Pharmaceuticals Quviviq (daridorexant h...

latest-news-card-1
Human Drugs

ODAC Discussing Immune Checkpoint Inhibitors

FDA issues two briefing documents to facilitate discussion by the Oncology Drugs Advisory Committee of the risk/benefit assessment of using immune che...

latest-news-card-1
Federal Register

Regulatory Review Period for Ojjaara

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for GlaxoSmithKlines Ojjaara (momelotinib).